Cargando…

Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis

INTRODUCTION: Combining measures of key core domains (especially pain and function) into a composite endpoint that requires each patient to meet a threshold of improvement for each domain provides information on multiple aspects of osteoarthritis within individual patients. This pooled analysis of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schnitzer, Thomas J., Berenbaum, Francis, Conaghan, Philip G., Dworkin, Robert H., Gatti, Davide, Yang, Ruoyong, Viktrup, Lars, Davignon, Isabelle, West, Christine R., Verburg, Kenneth M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572276/ https://www.ncbi.nlm.nih.gov/pubmed/34606077 http://dx.doi.org/10.1007/s40744-021-00372-2

Ejemplares similares

General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo‐Controlled Trials
por: Berenbaum, Francis, et al.
Publicado: (2022)

Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo‐controlled trials
por: Berenbaum, Francis, et al.
Publicado: (2021)

Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
por: Berenbaum, Francis, et al.
Publicado: (2021)

Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial
por: Markman, John D., et al.
Publicado: (2022)

Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis
por: Conaghan, Philip G., et al.
Publicado: (2022)

Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
por: Berenbaum, Francis, et al.
Publicado: (2020)

Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis
por: Birbara, Charles, et al.
Publicado: (2018)

Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip
por: Tive, Leslie, et al.
Publicado: (2019)

Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab
por: Hunter, D.J., et al.
Publicado: (2022)

Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study
por: Neogi, Tuhina, et al.
Publicado: (2022)

Response to: “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis”
por: Tive, Leslie A., et al.
Publicado: (2018)

Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis
por: Kan, Shun-Li, et al.
Publicado: (2016)

Clinical Outcomes of Tanezumab With Different Dosages for Patient With Osteoarthritis: Network Meta-Analysis
por: Hu, Rui, et al.
Publicado: (2021)

Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety
por: Markman, John D., et al.
Publicado: (2020)

Pooled Analysis of Tanezumab Efficacy and Safety with Subgroup Analyses of Phase III Clinical Trials in Patients with Osteoarthritis Pain of the Knee or Hip [Corrigendum]
Publicado: (2020)

Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain
por: Jonsson, E. Niclas, et al.
Publicado: (2016)

Various Doses of Tanezumab in the Management of Chronic Low Back Pain (CLBP): A Pooled Analysis of 4,514 Patients
por: Tahir, Sophia, et al.
Publicado: (2023)

Efficacy, General Safety, and Joint Safety of Tanezumab in Japanese Patients with Osteoarthritis: Subgroup Analyses from Two Randomized, Phase 3 Studies
por: Miki, Kenji, et al.
Publicado: (2022)

First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain
por: Walicke, Patricia A., et al.
Publicado: (2018)

Relative Efficacy and Safety of Tanezumab for Osteoarthritis: A Systematic Review and Meta-analysis of Randomized-Controlled Trials
por: Zhang, Bocheng, et al.
Publicado: (2021)

Tanezumab: Finally a Monoclonal Antibody for Pain Relief
por: Nair, Abhijit S
Publicado: (2018)

Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis
por: Patel, Mona K., et al.
Publicado: (2018)

Opioids for Osteoarthritis: Cross-Sectional Survey of Patient Perspectives and Satisfaction
por: Schnitzer, Thomas J., et al.
Publicado: (2023)

Factors associated with physician-reported treatment status of patients with osteoarthritis pain
por: Schnitzer, Thomas J., et al.
Publicado: (2022)

Tanezumab: a selective humanized mAb for chronic lower back pain
por: Webb, Michael P, et al.
Publicado: (2018)

New horizons and perspectives in the treatment of osteoarthritis
por: Berenbaum, Francis
Publicado: (2008)

Satisfaction with Medications Prescribed for Osteoarthritis: A Cross-Sectional Survey of Patients and Their Physicians in the United States
por: Robinson, Rebecca L., et al.
Publicado: (2022)

Brief Report: A Phase IIb Trial of a Novel Extended‐Release Microsphere Formulation of Triamcinolone Acetonide for Intraarticular Injection in Knee Osteoarthritis
por: Conaghan, Philip G., et al.
Publicado: (2017)

Examining the Relationships Among Treatment, Pain, and Physical Function in Patients With Osteoarthritis: A Mediation-Modeling Approach
por: Abraham, Lucy, et al.
Publicado: (2023)

The quest for the Holy Grail: a disease-modifying osteoarthritis drug
por: Berenbaum, Francis
Publicado: (2007)

Opioid Prescribing for Osteoarthritis: Cross-Sectional Survey among Primary Care Physicians, Rheumatologists, and Orthopaedic Surgeons
por: Schnitzer, Thomas J., et al.
Publicado: (2023)

Rescue Analgesic Medication Use by Patients Treated with Triamcinolone Acetonide Extended-Release for Knee Osteoarthritis Pain: Pooled Analysis of Three Phase 2/3 Randomized Clinical Trials
por: Kivitz, Alan J., et al.
Publicado: (2019)

Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials
por: Zhao, Di, et al.
Publicado: (2022)

Prospects for Therapies in Osteoarthritis
por: Ghouri, Asim, et al.
Publicado: (2020)

Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model
por: LaBranche, Timothy P, et al.
Publicado: (2017)

Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis
por: Louati, Karine, et al.
Publicado: (2015)

Measuring the impact and distress of osteoarthritis from the patients' perspective
por: Pallant, Julie F, et al.
Publicado: (2009)

Update on novel pharmacological therapies for osteoarthritis
por: Ghouri, Asim, et al.
Publicado: (2019)

Cartilage-gut-microbiome axis: a new paradigm for novel therapeutic opportunities in osteoarthritis
por: Berthelot, Jean-Marie, et al.
Publicado: (2019)

The optimal endpoint of resuscitation in trauma patients
por: Marik, Paul E
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_k2o207vm1cfjfrejgnaqquugbf